title: Accuracy of magnetic resonance imaging in predicting residual disease in patients treated for stage IB2/II cervical carcinoma with chemoradiation therapy : correlation of radiologic findings with surgicopathologic results.
abstract: BACKGROUND
  The evaluation of residual disease (RD) after chemoradiation therapy (CRT) in stage IB2/II cervical carcinoma conventionally is based on a clinical examination and magnetic resonance imaging (MRI) performed 3 to 8 weeks after the end of treatment. Very few studies have correlated MRI and histologic findings specifically in cervix cancer. This was the objective of the current study.
  
  
  METHODS
  A retrospective review was undertaken of patients who fulfilled the following inclusion criteria: 1) stage IB2/II cervical cancer, 2) external radiotherapy (45 grays [Gy]) was given with concomitant chemotherapy followed by uterovaginal brachytherapy (15 Gy), 3) MRI studies were obtained between 3 weeks and 8 weeks after brachytherapy, and 4) completion surgery included at least a hysterectomy. Postsurgical histologic findings and MRI results were compared.
  
  
  RESULTS
  Forty-four patients who were treated between 2003 and 2006 fulfilled all inclusion criteria. Twelve patients (27%) had achieved a radiologic complete response, 16 patients (36.5%) had unclassified lesions (RD or 'fibrosis'), and 16 patients (36.5%) had radiologic residual tumor. According to the histologic results, 19 patients (43%) had no RD, 10 patients (23%) had inframillimeter RD, 2 patients (5%) had RD that measured <1 cm, and 13 patients (29%) had RD that measured >1 cm. The sensitivity and specificity of MRI in evaluating RD were 80% and 55%, respectively.
  
  
  CONCLUSIONS
  The current results indicated that the evaluation of RD 3 to 8 weeks after CRT with MRI is difficult, and the risk of false-positive results is high. Another radiologic procedure or a more technologically advanced MRI technique, such as diffusion-weighted MRI, should be evaluated.
authors.affiliation: Department of Surgery, Gustave Roussy Institute and South Paris University, Villejuif, France.
authors.forename: Etienne
authors.initials: E
authors.lastname: Vincens
authors.forename: Corinne
authors.initials: C
authors.lastname: Balleyguier
authors.forename: Annie
authors.initials: A
authors.lastname: Rey
authors.forename: Catherine
authors.initials: C
authors.lastname: Uzan
authors.forename: Elise
authors.initials: E
authors.lastname: Zareski
authors.forename: Sebastien
authors.initials: S
authors.lastname: Gouy
authors.forename: Patricia
authors.initials: P
authors.lastname: Pautier
authors.forename: Pierre
authors.initials: P
authors.lastname: Duvillard
authors.forename: Christine
authors.initials: C
authors.lastname: Haie-Meder
authors.forename: Philippe
authors.initials: P
authors.lastname: Morice
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001918:Brachytherapy; D002277:Carcinoma / Q000175:diagnosis* / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D013509:Gynecologic Surgical Procedures; D006801:Humans; D007090:Image Interpretation, Computer-Assisted; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D018365:Neoplasm, Residual; D017671:Platinum Compounds / Q000627:therapeutic use; D011878:Radiotherapy; D012680:Sensitivity and Specificity; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis* / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents; D017671:Platinum Compounds